UK markets open in 4 hours 34 minutes
NIKKEI 225
28,818.53 -42.09 (-0.15%) HANG SENG
24,286.63 +289.76 (+1.21%) CRUDE OIL
73.23 +0.87 (+1.20%) GOLD FUTURES
1,783.50 -2.00 (-0.11%) DOW
35,754.75 +35.32 (+0.10%) BTC-GBP
37,777.87 -583.76 (-1.52%)
Allergy Therapeutics plc (AGY.L)
LSE - LSE Delayed price. Currency in GBp
Add to watchlist
At close: 04:05PM GMT
| Previous close | 35.50 |
| Open | 35.00 |
| Bid | 34.00 x 0 |
| Ask | 36.00 x 0 |
| Day's range | 34.00 - 36.00 |
| 52-week range | 14.11 - 40.50 |
| Volume | |
| Avg. volume | 340,965 |
| Market cap | 224.63M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | 87.50 |
| EPS (TTM) | 0.40 |
| Earnings date | 23 Sept 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 59.00 |
- Simply Wall St.
These 4 Measures Indicate That Allergy Therapeutics (LON:AGY) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Globe Newswire
Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL Primary endpoint Combined Symptom Medication Score (CSMS) achieved with clinically relevant improvement across both active treatment groups compared to placebo Statistically significant reduction in CSMS seen in both active treatment groups of 29.1% and 36.8% compared to placebo Analysis
- Simply Wall St.
Is Allergy Therapeutics plc's (LON:AGY) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Allergy Therapeutics' (LON:AGY) stock is up by a considerable 48% over the past three months. We wonder if and what...
© 2021 Yahoo. All rights reserved.
